Search International and National Patent Collections

1. (WO2016054555) COMBINATION THERAPIES

Pub. No.:    WO/2016/054555    International Application No.:    PCT/US2015/053799
Publication Date: Fri Apr 08 01:59:59 CEST 2016 International Filing Date: Sat Oct 03 01:59:59 CEST 2015
IPC: A61K 31/00
A61K 39/395
A61P 35/00
C07K 16/28
Applicants: NOVARTIS AG
CAO, Zhu, Alexander
RONG, Xianhui
PINZON-ORTIZ, Maria, Consuelo
LONGMIRE, Tyler
LEE, Benjamin, Hyun
Inventors: CAO, Zhu, Alexander
RONG, Xianhui
PINZON-ORTIZ, Maria, Consuelo
LONGMIRE, Tyler
LEE, Benjamin, Hyun
Title: COMBINATION THERAPIES
Abstract:
Combination therapies are disclosed. The combination therapies can be used to treat or prevent cancerous conditions and/or disorders. The combination may comprise an immunomodulator and a second therapeutic agent, wherein: (i) the immunomodulator is an inhibitor of an immune checkpoint molecule chosen from the list of inhibitors of one or more of PD-1, PD L1, PD-L2, CTLA-4, TIM-3, LAG-3, CEACAM, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 or TGFR beta, or the immunomodulator is an activator of a costimulatory molecule chosen from the list of agonists of one or more of OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3 or CD83 ligand, and wherein (ii) the second therapeutic agent is chosen from one or more compounds as provided in Table 1, i.e. LCL 161, Rad-001 (Evrolimus), CGM097, LGH-447, LJM716 (Human monoclonal antibody), LBH589 (Panobinostat), INC424 (Ruxolitinib), BUW078 or BGJ398.